Group 1 - The company provided an update on its subsidiary Minwei Biopharmaceutical's pipeline development and clinical trials, indicating that MWN109 injection and MWN105 injection are currently in Phase II clinical trials [2] - The oral MWN109 tablet is in the preparatory stage for Phase II clinical trials, while MWX203 injection is in Phase I clinical trials [2] - The company expressed gratitude for investor interest in the progress of its drug development and collaborations with multinational pharmaceutical companies [2]